Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

NCT02252146 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Idera Pharmaceuticals, Inc.